Home › Calculator › GMAB Dividend Calculator 2026
GMAB Dividend DRIP Calculator 2026
7.28% YieldHealthcareGenmab A/S · NASDAQ
Price: $27.47 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When GMAB pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your GMAB snowball 📈
$10,000 in GMAB → $546.60M in 10 years · $44,947,364.46/month
About Genmab A/S (GMAB) — Dividend Analysis 2026
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Compare GMAB with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full GMAB DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GMAB position with:
🌍 GMAB Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold GMAB.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 7.28% | 4.48% | $728 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 6.19% | 3.39% | $619 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 5.82% | 3.02% | $582 / yr |
| 🇬🇧 UK ISA | 0% | 7.28% | 4.48% | $728 / yr |
| 🇬🇧 UK Taxable | 8.75% | 6.64% | 3.84% | $664 / yr |
| 🇨🇦 TFSA | 0% | 7.28% | 4.48% | $728 / yr |
| 🇨🇦 CA Taxable | 25% | 5.46% | 2.66% | $546 / yr |
| 🇦🇺 Super (pension) | 15% | 6.19% | 3.39% | $619 / yr |
| 🇦🇺 AU Taxable | 30% | 5.10% | 2.30% | $510 / yr |
| 🇩🇪 DE Taxable | 26.375% | 5.36% | 2.56% | $536 / yr |
| 🇫🇷 FR Taxable | 30% | 5.10% | 2.30% | $510 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 GMAB Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 GMAB Dividend Payment Schedule
GMAB pays quarterly — 4 times per year. Next ex-div: TBD.
📊 GMAB vs Healthcare Benchmarks
How GMAB compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GMAB sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ GMAB Insider Activity
No recent SEC filings reported in the last 90 days.Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GMAB dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Genmab A/S (GMAB) is currently trading at $27.47, 43% below its 52-week high. The current dividend yield is 7.28% based on an annual payout of $2.00 per share.
GMAB (Genmab A/S) — 7.28% Dividend Yield Analysis
Genmab A/S (GMAB) is a healthcare stock currently trading at $27.47 with a dividend yield of 7.28%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (7.28%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest GMAB News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.